Krystal Biotech Stock Debt To Equity
| KRYS Stock | USD 188.61 0.57 0.30% |
Krystal Biotech fundamentals help investors to digest information that contributes to Krystal Biotech's financial success or failures. It also enables traders to predict the movement of Krystal Stock. The fundamental analysis module provides a way to measure Krystal Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Krystal Biotech stock.
Krystal |
Krystal Biotech Company Debt To Equity Analysis
Krystal Biotech's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Krystal Biotech Debt To Equity | 0.02 % |
Most of Krystal Biotech's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Krystal Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Krystal Biotech has a Debt To Equity of 0.016%. This is 99.97% lower than that of the Biotechnology sector and 99.92% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.97% higher than that of the company.
Krystal Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Krystal Biotech's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Krystal Biotech could also be used in its relative valuation, which is a method of valuing Krystal Biotech by comparing valuation metrics of similar companies.Krystal Biotech is currently under evaluation in debt to equity category among its peers.
Krystal Fundamentals
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0688 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 4.86 B | ||||
| Shares Outstanding | 28.81 M | ||||
| Shares Owned By Insiders | 12.23 % | ||||
| Shares Owned By Institutions | 87.77 % | ||||
| Number Of Shares Shorted | 3.19 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 5.76 X | ||||
| Price To Sales | 18.76 X | ||||
| Revenue | 290.51 M | ||||
| Gross Profit | 270.45 M | ||||
| EBITDA | 109.91 M | ||||
| Net Income | 89.16 M | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 7.26 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.45 X | ||||
| Book Value Per Share | 32.87 X | ||||
| Cash Flow From Operations | 123.42 M | ||||
| Short Ratio | 10.41 X | ||||
| Earnings Per Share | 3.01 X | ||||
| Target Price | 214.8 | ||||
| Number Of Employees | 275 | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 5.45 B | ||||
| Total Asset | 1.06 B | ||||
| Retained Earnings | (180.67 M) | ||||
| Working Capital | 640.05 M | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
| Net Asset | 1.06 B |
About Krystal Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.